C
C. Leonardi
Researcher at Saint Louis University
Publications - 32
Citations - 1574
C. Leonardi is an academic researcher from Saint Louis University. The author has contributed to research in topics: Psoriasis Area and Severity Index & Psoriasis. The author has an hindex of 12, co-authored 30 publications receiving 1308 citations.
Papers
More filters
Journal ArticleDOI
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana,Anthony Ormerod,Philippe Saiag,Catherine H. Smith,Ph.I. Spuls,Alexander Nast,Jonathan Barker,Jan D. Bos,GR Burmester,Sergio Chimenti,L Dubertret,Bernadette Eberlein,R. Erdmann,J. Ferguson,Giampiero Girolomoni,Paolo Gisondi,Alessandro Giunta,Christopher E.M. Griffiths,Herbert Hönigsmann,Munther Hussain,Ray Jobling,SL Karvonen,Lajos Kemény,Ina Kopp,C. Leonardi,Mara Maccarone,Alan Menter,Ulrich Mrowietz,Luigi Naldi,Tamar Nijsten,Ortonne Jp,Hans-Dieter Orzechowski,Taina Rantanen,Kristian Reich,Natalie Reytan,H Richards,H.B. Thio,P.C.M. van de Kerkhof,B. Rzany +38 more
TL;DR: Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
Journal ArticleDOI
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar,Philip J. Mease,I.B. McInnes,Xenofon Baraliakos,Kristian Reich,A Blauvelt,C. Leonardi,Brian Porter,A Das Gupta,A Widmer,Luminita Pricop,Todd Fox +11 more
TL;DR: This comprehensive assessment demonstrated that the safety profile of secukinumab was consistent with previous reports in patients with PsO, PsA, and AS, supporting its long-term use in these chronic conditions.
Journal ArticleDOI
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Robert Bissonnette,T. A. Luger,Diamant Thaçi,D. Toth,A. Lacombe,Summer Xia,Rafal Mazur,Manmath Patekar,Pascal Charef,M. Milutinovic,C. Leonardi,Ulrich Mrowietz +11 more
TL;DR: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis.
Journal ArticleDOI
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Alice B. Gottlieb,C. Leonardi,Francisco A. Kerdel,Stephanie L Mehlis,M. Olds,David A. Williams +5 more
TL;DR: The anti‐interleukin‐12/23p40 monoclonal antibody briakinumab has been shown in a phase II study to be effective psoriasis treatment.
Journal Article
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
C. Leonardi,Jerry Bagel,Paul S. Yamauchi,David M. Pariser,Xu Z,Olesen M,Osterdal Ml,Stein Gold L +7 more
TL;DR: Cal/BD foam was efficacious, achieved rapid itch relief and was well tolerated in patients with body psoriasis and this innovative aerosol foam formulation is expected to become a valuable treatment option.